EnzymeBioSystems Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-01-04: Form 8-K; Period of report 2017-12-28; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2017-12-14: Form 8-K; Period of report 2017-12-12; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2017-10-03: Form 8-K; Period of report 2017-09-28; Description 8.01 Other Events; Details 8.01.
- 2017-02-27: Form 8-K/A; Period of report 2017-01-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-01-04 | 8-K | 2017-12-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 27, 2017, the majority shareholders of EnzymeBioSystems (the “Company” or the “Registrant”) voted to realign the Officers in the Company by appointing John Dean Harper to the Board of Directors as the sole Director. | form8-k.htm |
| 2017-12-14 | 8-K | 2017-12-12 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 EnzymeBioSystems (the “Company” or the “Registrant”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a sixteen accredited investors (the “Purchasers”) pursuant to which the Company has agreed to issue and sell to the Purchasers the offering (the “Offering”) an aggregate of 2,759,775 units at a public offering price of $0.20 per unit, with each unit consisting of (i) one share of the Company’s Common Stock, par value $0.001 (the “Common Stock” and such shares of Common Stock issued upon the closing of the Offering, collectively, the “Shares”), (ii) one Class A warrant to purchase one share of Common Stock, (iii) one Class B warrant to purchase one share of Common Stock (iv) one Class C warrant to purchase one share of Common Stock, and (v) one Class D cashless warrant to purchase one share of Common Stock provided the Class C warrant is exercised, (the Class A, B, C, and D warrants shall be collectively, the “Warrants” and the shares issuable upon exercise of the Warrants, collectively, the “Warrant Shares”). 3.02 During September, 2017 through December 2017, the Company conducted a private offering in which it sold 2,760,000 units shares of the Company’s $0.001 par value common stock, that includes A, B, C & D warrants in exchange for cash of $551,945.00. 8.01 EnzymeBioSystems, has changed its corporate headquarters from: 8440 W. Lake Mead, Suite 214, Las Vegas, NV 89128 to 8250 W. Charleston Blvd. | form8-k.htm |
| 2017-10-03 | 8-K | 2017-09-28 | 8.01 Other Events | 8.01 On September 28, 2017, EnzymeBioSystems ("the Company") received a Notice of Allowance from the U.S. Patent Office that they approved the Company’s Patent Application #14/369339 entitled "Amooranin Compounds and Analogs Thereof and Related Methods of Use." A Notice of Allowance is issued by the United States Patent & Trademark Office to indicate that it believes an invention qualifies for a patent. | allowance8k.htm |
| 2017-02-27 | 8-K/A | 2017-01-17 | 8.01 Other Events | 8.01 On January 17, 2017, the Board of Directors and a majority shareholders of EnzymeBioSystems ("the Company") approved the dividend spin-off of the Company's wholly owned subsidiary, Shareholder Acquisition Corp. The Company incorporated Shareholder Acquisition Corp., a Nevada corporation, as its wholly owned subsidiary on January 10, 2017. | dividend8ka.htm |
| 2017-01-17 | 8-K | 2017-01-17 | 8.01 Other Events | 8.01 On January 17, 2017, the Board of Directors and a majority shareholders of EnzymeBioSystems ("the Company") approved the dividend spin-off of the Company's wholly owned subsidiary, Shareholder Acquisition Corp. The Company incorporated Shareholder Acquisition Corp., a Nevada corporation, as its wholly owned subsidiary on January 10, 2017. | dividend8k.htm |
| 2015-10-14 | 8-K | 2015-10-09 | 4.01 Changes in Registrant's Certifying Accountant; 8.01 Other Events | 4.01 On October 9, 2015, EnzymeBioSystems (the “Company”) was notified by its independent registered public accounting firm, Seale & Beers, CPAs (“Seale & Beers”), that it is resigning its engagement as the Company’s independent registered public accounting firm. 8.01 The Registrant has changed its principal executive offices from 8250 W. Charleston Blvd., Suite 120, Las Vegas, NV 89117, to: 8440 W. Lake Mead, Suite 214, Las Vegas, NV 89128. | enzb8kauditor.htm |
| 2015-09-25 | 8-K | 2015-09-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 21, 2015, the Board of Directors ("Board") and shareholders who own 63.6% of the Company's voting stock of EnzymeBioSystems (the “Company” or the “Registrant”) approved the dismissal of the Company's former CFO and Board member, Edward Zimmerman III; for cause, based on breach of his fiduciary duties. | enzb8kchange.htm |
| 2015-08-20 | 8-K | 2015-08-20 | 7.01 Regulation FD Disclosure | 7.01 A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. | aenzb8k.htm |
| 2014-10-23 | 8-K | 2014-10-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On October 20, 2014, the Board of Directors of EnzymeBioSystems ("the Company" or the "Registrant") accepted the resignation of Mr. Anushavan Yeranosyan, in his position as Chief Accounting Officer and Director of the Corporation. 8.01 The Registrant has changed its principal executive offices to: 7575 W. Washington Ave., #127, Las Vegas, NV 89128; from: 16773 W Park Drive, Chagrin Falls, Ohio 44023. | enzb8k.htm |
| 2014-06-13 | 8-K | 2014-06-09 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 On June 9, 2014, EnzymeBiosSystems (“the Company” or the Registrant”) closed its Regulation S Offering, whereby, the Company sold 12,783,587 shares of unregistered restricted common stock to six foreign purchasers, at a price of $0.0766 per share. 8.01 Berkeley Clinic, LC, an Arizona Limited Liability Company has agreed to cancel 11,000,000 of their common shares. | enzb8k.htm |
| 2014-06-05 | 8-K | 2014-06-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 2, 2014, the Board of Directors of EnzymeBioSystems (the “Company” or the “Registrant”) unanimously appointed Mr. Gary Rojewski as Chief Executive Officers of the Company. | enzb8k.htm |
| 2014-05-06 | 8-K | 2014-05-02 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 On May 2, 2014, EnzymeBioSystems (the “Company”) entered into a Purchase Agreement with Berkeley Clinic LC, an Arizona Limited Liability Company, ("Berkeley") whereby EnzymeBioSystems, purchased all rights, title and interest in all patents, both U.S. and foreign, as well as any technology developed by the Company that was owned by Berkeley in exchange for 4,000,000 Series A Preferred Shares, 11,000,000 unregistered restricted common shares owned by Berkeley and $438,000. 3.02 On May 2, 2014, EnzymeBioSystems issued 4,000,000 unregistered restricted shares of Series A Preferred Stock to Berkeley Clinic, LC in order to satisfy the terms of a Purchase Agreement with Berkeley. | enzb8k.htm |
| 2011-02-01 | 8-K | 2011-01-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.06 Change in Shell Company Status | enzyme8k.txt | |
| 2010-05-06 | 8-K | 2010-05-05 | 8.01 Other Events | enzyme8knw.txt |